Cardiotoxicity is a serious adverse reaction to
cancer chemotherapy and may lead to critical heart damage.
Imatinib mesylate (IMB), a selective
tyrosine kinase inhibitor, is sometimes accompanied by severe cardiovascular complications. To minimize risk, early
biomarkers of such complications are of utmost importance. At the present time,
microRNAs (
miRNAs) are intensively studied as potential
biomarkers of many
pathological processes. Many
miRNAs appear to be specific in some tissues, including the heart. In the present study we have explored the potential of specific
miRNAs to be early markers of IMB-induced
cardiotoxicity.
Doxorubicin (DOX), an
anthracycline with well-known
cardiotoxicity, was used for comparison. NMRI mice were treated with IMB or DOX for nine days in doses corresponding to the highest recommended doses in oncological patients, following which plasmatic levels of
miRNAs were analyzed in
miRNA microarrays and selected cardio-specific
miRNAs were quantified using qPCR. The plasmatic level of miR-1a, miR-133a, miR-133b, miR-339, miR-7058, miR-6236 and miR-6240 were the most different between the IMB-treated and control mice. Interestingly, most of the
miRNAs affected by DOX were also affected by IMB showing the same trends. Concerning selected
microRNAs in the hearts of individual mice, only miR-34a was significantly increased after DOX treatment, and only miR-205 was significantly decreased after IMB and DOX treatment. However, no changes in any
miRNA expression correlated with the level of
troponin T, a classical marker of
heart injury.